EUR 32.66
(2.7%)
Year | Total Liabilities | Total Liabilities Growth |
---|---|---|
2023 | 12.84 Million SEK | 39.9% |
2022 | 9.18 Million SEK | 21.18% |
2021 | 7.57 Million SEK | 14.79% |
2020 | 6.59 Million SEK | -3.71% |
2019 | 6.85 Million SEK | 45.91% |
2018 | 4.69 Million EUR | -68.34% |
2017 | 14.83 Million EUR | -7.97% |
2016 | 16.12 Million EUR | 0.0% |
Year | Total Liabilities | Total Liabilities Growth |
---|---|---|
2024 Q3 | 116.84 Million SEK | -5.16% |
2024 Q1 | 13.72 Million SEK | 7.76% |
2024 Q2 | 123.21 Million EUR | -20.4% |
2023 Q3 | 8.74 Million SEK | 10.06% |
2023 Q4 | 12.84 Million SEK | 46.96% |
2023 FY | 12.84 Million SEK | 39.9% |
2023 Q2 | 7.94 Million SEK | -13.89% |
2023 Q1 | 9.22 Million SEK | 0.45% |
2022 Q4 | 9.18 Million SEK | 16.23% |
2022 Q1 | 7.62 Million EUR | 0.68% |
2022 Q2 | 7.13 Million EUR | -6.49% |
2022 Q3 | 7.89 Million EUR | 10.75% |
2021 Q4 | 7.57 Million EUR | 0.0% |
Name | Total Liabilities | Total Liabilities Difference |
---|---|---|
SCHOTT Pharma AG & Co. KGaA | 539.64 Million EUR | 97.62% |
Carl Zeiss Meditec AG | 860.02 Million EUR | 98.506% |
Fielmann Aktiengesellschaft | 1.2 Billion EUR | 98.938% |
Gerresheimer AG | 1.95 Billion EUR | 99.344% |
Sartorius Aktiengesellschaft | 6.99 Billion EUR | 99.816% |
Sartorius Aktiengesellschaft | 6.99 Billion EUR | 99.816% |